Literature DB >> 9835504

Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats.

S Kojima1, M Nadai, K Kitaichi, L Wang, T Nabeshima, T Hasegawa.   

Abstract

There is evidence indicating that the carbapenem antibiotic panipenem decreases plasma concentrations of valproic acid (VPA) in epileptic patients during VPA therapy. The mechanism for panipenem-induced changes in the pharmacokinetics of VPA was investigated in rats with and without bile duct cannulation. The effect of panipenem on the pharmacokinetics of diclofenac, which undergoes extensive enterohepatic recirculation, was also examined. VPA (50 mg/kg of body weight) or diclofenac (10 mg/kg of body weight) was administered intravenously under the steady-state plasma panipenem concentration of 4 microgram/ml, which had been achieved by a constant infusion rate. Panipenem decreased the plasma VPA concentrations in rats without bile duct cannulation but did not change the volume of the initial space and protein binding of VPA. However, panipenem had no effect on the plasma VPA concentrations and the biliary excretion of VPA in rats with bile duct cannulation. The secondary increase in plasma diclofenac concentration observed in the absence of panipenem was diminished in the presence of panipenem. These findings suggest that panipenem decreases plasma VPA concentrations by suppressing its enterohepatic recirculation, probably due to a panipenem-induced decrease in the numbers of enteric bacteria.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9835504      PMCID: PMC106012     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  A rapid and sensitive high-performance liquid chromatographic method for the determination of diclofenac sodium in serum and its use in pharmacokinetic studies.

Authors:  Y M el-Sayed; M E Abdel-Hameed; M S Suleiman; N M Najib
Journal:  J Pharm Pharmacol       Date:  1988-10       Impact factor: 3.765

2.  Disposition and pharmacokinetics of valproic acid in rats.

Authors:  T Ogiso; Y Ito; M Iwaki; T Yamahata
Journal:  Chem Pharm Bull (Tokyo)       Date:  1986-07       Impact factor: 1.645

3.  Gas chromatographic measurement of plasma levels of sodium valproate: tentative therapeutic range of a new anticonvulsant in the treatment of refractory epileptics.

Authors:  F J Vajda; O H Drummer; P M Morris; J J McNeil; P F Bladin
Journal:  Clin Exp Pharmacol Physiol       Date:  1978 Jan-Feb       Impact factor: 2.557

4.  Influence of albumin on the distribution and elimination kinetics of diclofenac in the isolated perfused rat liver: analysis by the impulse-response technique and the dispersion model.

Authors:  A M Evans; Z Hussein; M Rowland
Journal:  J Pharm Sci       Date:  1993-04       Impact factor: 3.534

5.  Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat.

Authors:  G M Pollack; K L Brouwer
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

6.  Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation.

Authors:  B K Reuter; N M Davies; J L Wallace
Journal:  Gastroenterology       Date:  1997-01       Impact factor: 22.682

7.  Pharmacokinetics and pharmacodynamics of valproate analogs in rats. II. Pharmacokinetics of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid.

Authors:  M J Liu; G M Pollack
Journal:  Biopharm Drug Dispos       Date:  1993-05       Impact factor: 1.627

8.  Steady-state kinetics of valproic acid in epileptic patients.

Authors:  J Bruni; B J Wilder; L J Willmore; R J Perchalski; H J Villarreal
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

9.  In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.

Authors:  Y Fukuoka; Y Ikeda; Y Yamashiro; M Takahata; Y Todo; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Clinical implications of serum protein binding in epileptic children during sodium valproate maintenance therapy.

Authors:  H Y Yu
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

View more
  9 in total

1.  Ertapenem-induced reduction in valproate levels: case report and review of the literature.

Authors:  Duane Bates; Michael Parkins; Keltie Duggan
Journal:  Can J Hosp Pharm       Date:  2010-07

Review 2.  Panipenem/betamipron.

Authors:  Karen L Goa; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits.

Authors:  K Yokogawa; S Iwashita; A Kubota; Y Sasaki; J Ishizaki; M Kawahara; R Matsushita; K Kimura; F Ichimura; K Miyamoto
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

4.  Valproate Interaction With Carbapenems: Review and Recommendations.

Authors:  Osama Al-Quteimat; Alla Laila
Journal:  Hosp Pharm       Date:  2019-02-22

5.  Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient.

Authors:  Hiroaki Ikeda; Teruo Murakami; Mikihisa Takano; Tsuguru Usui; Kenji Kihira
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

6.  Influence of enterohepatic recycling on the time course of brain-to-blood partitioning of valproic acid in rats.

Authors:  Jeannie M Padowski; Gary M Pollack
Journal:  Drug Metab Dispos       Date:  2012-06-19       Impact factor: 3.922

Review 7.  Drug Interactions in Neurocritical Care.

Authors:  Brian Spoelhof; Salia Farrokh; Lucia Rivera-Lara
Journal:  Neurocrit Care       Date:  2017-10       Impact factor: 3.210

8.  Enteric reabsorption processes and their impact on drug pharmacokinetics.

Authors:  Manuel Ibarra; Iñaki F Trocóniz; Pietro Fagiolino
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

Review 9.  Potential roles of gut microbiota and microbial metabolites in chronic inflammatory pain and the mechanisms of therapy drugs.

Authors:  Jia-Shang Li; Shu-Lan Su; Zhuo Xu; Li-Hui Zhao; Ruo-Ying Fan; Jian-Ming Guo; Da-Wei Qian; Jin-Ao Duan
Journal:  Ther Adv Chronic Dis       Date:  2022-07-28       Impact factor: 4.970

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.